@article {Yamamoto:2009:0929-8673:1349,
title = "Pharmacological Implications of MMP-9 Inhibition by ACE Inhibitors",
journal = "Current Medicinal Chemistry",
parent_itemid = "infobike://ben/cmc",
publishercode ="ben",
year = "2009",
volume = "16",
number = "11",
publication date ="2009-04-01T00:00:00",
pages = "1349-1354",
itemtype = "ARTICLE",
issn = "0929-8673",
url = "https://www.ingentaconnect.com/content/ben/cmc/2009/00000016/00000011/art00003",
doi = "doi:10.2174/092986709787846514",
keyword = "cardiovascular protection, myocardial infarction, angiotensin converting enzyme inhibitor, inhibitory specificity, coronary diseases, molecular interaction, Matrix metalloproteinase-9, angiotensin II receptor blocker",
author = "Yamamoto, Daisuke and Takai, Shinji",
abstract = "Matrix metalloproteinase-9 (MMP-9) plays an important role in the onset and prognosis of myocardial infarction. Targets of angiotensin converting enzyme (ACE) inhibitors might include not only ACE but also MMP-9, and ACE seems to be closely associated with complications of hypertension such as cardiovascular remodeling whereas MMP-9 is closely related to coronary diseases. We postulate that ACE inhibitors prevent coronary diseases via direct MMP-9 inhibition and could interact with the MMP-9 active sites using specific modes similar to those used for the ACE active sites. Research of the molecular interaction between MMP-9 active sites and ACE inhibitors appears to be an important key in the development of effective MMP-9 inhibitors for cardiovascular protection.",
}